Form 4 Filing for Arcus Biosciences, Inc.

This filing details transactions by Kathryn E. Falberg, a director at Arcus Biosciences, Inc. On June 11, 2026, Falberg acquired 5,700 shares of Common Stock and was granted 16,900 Stock Options. The Common Stock acquisition is marked with a footnote indicating it represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027, or the next annual stockholder meeting, and will fully vest upon a change in control. The acquired shares are part of a trust holding, with 132,106 shares owned following the transaction. The Stock Option grant also vests under similar conditions, including full vesting upon a change in control. The option has an exercise price of $23.30 and expires on June 10, 2036. Another footnote mentions that 30,000 shares were previously reported as held directly by the reporting person.